Regeneron Pharmaceuticals (REGN) Stock Price, Quote & News

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology

Sector: Healthcare

Phone: 914 847 7000

Website: www.regeneron.com

Address:

777 Old Saw Mill River Road, Tarrytown, United States

SuperGreenToday Oct. 25 at 1:24 AM

$REGN Share Price: $578.09 Contract Selected: Nov 21, 2025 $580 Calls Buy Zone: $20.48 – $25.31 Target Zone: $36.20 – $44.24 Potential Upside: 67% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OTCMOBSTER Oct. 24 at 9:29 PM

$REGN My grandfather passed down some $REGN shares he’d been holding since 1994, and they’re now helping fund my retirement. I’m looking for some hidden gems to research and hold long-term—say, for the next 20 years. Any ideas worth doing some DD on?

1 · Reply

OX50 Oct. 24 at 9:08 PM

$REGN Latest Report 10/24/2025 LSEG maintains a current price target of $733.14 for REGN

0 · Reply

MahiMe Oct. 24 at 8:06 PM

$REGN https://finance.yahoo.com/news/long-leaf-partners-fund-regeneron-171424649.html Longleaf Partners Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its third quarter 2025 investor letter: "After a slow start to our holding period this year, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has found its footing and grown its value per share back to above where we started the year in our opinion. We still do not have to pay anything for multiple high quality pipeline candidates, and the company has become one of our larger share repurchasers with its net cash balance sheet."

0 · Reply

BryanNewton Oct. 24 at 7:57 PM

$REGN I heard the company is doing well. They got some nice drugs coming in their pipeline

0 · Reply

LiquidThetaLEAPS Oct. 24 at 7:51 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $REGN Current Share Price: $573.95 Contracts: $REGN December 18, 2026 $580 Calls Scale in: $93.60- $114.40 Scale out: $145.60-$187.20 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

MahiMe Oct. 24 at 6:12 PM

$REGN giddy up. 585+.. today

0 · Reply

Bullish_Trader555 Oct. 24 at 2:44 PM

$MRUS $SPY $LLY $REGN

0 · Reply

Bullish_Trader555 Oct. 24 at 2:09 PM

$MRUS Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) - $SPY $LLY $REGN

0 · Reply

MahiMe Oct. 24 at 1:00 PM

$REGN Canaccord Genuity has maintained a "Buy" rating for Regeneron Pharmaceuticals (REGN) with a price target of $850, as of an analyst note published on October 23, 2025

0 · Reply

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FI IQV IVZ JNJ

Oct 23, 2025, 7:30 PM EDT - 1 day ago

7 Stocks Taking The Next Step To Be On Offense

ACI BIO CNX FCF FDX FIS IAC

Oct 17, 2025, 7:30 AM EDT - 8 days ago

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 15, 2025, 7:00 AM EDT - 10 days ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Oct 12, 2025, 10:18 AM EDT - 13 days ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Oct 10, 2025, 8:35 AM EDT - 15 days ago

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

Oct 8, 2025, 4:31 PM EDT - 16 days ago

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

Oct 8, 2025, 2:31 PM EDT - 16 days ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 7, 2025, 11:49 AM EDT - 18 days ago

11 Cheap Stocks for a Market That's Too Expensive

DAL FDX UAL

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Sep 30, 2025, 4:25 PM EDT - 24 days ago

Regeneron: Growth Catalysts Incoming

Sep 30, 2025, 4:05 PM EDT - 24 days ago

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

Sep 30, 2025, 1:37 PM EDT - 24 days ago

Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin

APH LMT NVDA

Sep 27, 2025, 9:00 AM EDT - 4 weeks ago

Regeneron: Strong R&D Pipeline Drives Growth Outlook

Sep 26, 2025, 7:00 AM EDT - 4 weeks ago

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Sep 24, 2025, 1:37 PM EDT - 4 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Sep 23, 2025, 6:29 PM EDT - 4 weeks ago

Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises

Sep 22, 2025, 12:30 AM EDT - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

SNY

Sep 22, 2025, 12:29 AM EDT - 4 weeks ago

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Sep 19, 2025, 1:23 PM EDT - 5 weeks ago

Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study

Sep 19, 2025, 7:00 AM EDT - 5 weeks ago

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

Sep 17, 2025, 7:27 AM EDT - 5 weeks ago

Regeneron's bone disorder treatment succeeds in late-stage trial

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Sep 8, 2025, 2:35 PM EDT - 6 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 1:11 PM EDT - 6 weeks ago

What's Happening With Regeneron Pharmaceuticals Stock On Monday?

Sep 4, 2025, 4:05 PM EDT - 7 weeks ago

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

Sep 4, 2025, 4:03 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 4:46 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 2, 2025, 6:30 PM EDT - 7 weeks ago

Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

Aug 29, 2025, 1:34 PM EDT - 2 months ago

Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial

CSCO NOW TFC

Aug 26, 2025, 7:22 AM EDT - 2 months ago

Regeneron's rare immune disorder therapy meets main goal of late-stage trial

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Aug 21, 2025, 1:20 PM EDT - 2 months ago

A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs

JNJ

Aug 20, 2025, 11:19 AM EDT - 2 months ago

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

Aug 11, 2025, 11:36 AM EDT - 2 months ago

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

Aug 4, 2025, 2:05 PM EDT - 2 months ago

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

Aug 1, 2025, 4:05 PM EDT - 3 months ago

Regeneron: Rapidly Decreasing Importance Of Eylea

Aug 1, 2025, 1:46 PM EDT - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:01 PM EDT - 3 months ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD GSK JNJ

Aug 1, 2025, 10:10 AM EDT - 3 months ago

US FDA declines to approve Regeneron's blood cancer therapy for second time

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 8:22 AM EDT - 3 months ago

Regeneron beats second-quarter results estimates on Dupixent sales boost

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:30 AM EDT - 3 months ago

Regeneron Reports Second Quarter 2025 Financial and Operating Results

Aug 1, 2025, 5:17 AM EDT - 3 months ago

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jul 31, 2025, 3:35 PM EDT - 3 months ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 3:00 PM EDT - 3 months ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:28 PM EDT - 3 months ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD GSK JNJ

SuperGreenToday Oct. 25 at 1:24 AM

0 · Reply

OTCMOBSTER Oct. 24 at 9:29 PM

1 · Reply

OX50 Oct. 24 at 9:08 PM

$REGN Latest Report 10/24/2025 LSEG maintains a current price target of $733.14 for REGN

0 · Reply

MahiMe Oct. 24 at 8:06 PM

0 · Reply

BryanNewton Oct. 24 at 7:57 PM

$REGN I heard the company is doing well. They got some nice drugs coming in their pipeline

0 · Reply

LiquidThetaLEAPS Oct. 24 at 7:51 PM

0 · Reply

MahiMe Oct. 24 at 6:12 PM

$REGN giddy up. 585+.. today

0 · Reply

Bullish_Trader555 Oct. 24 at 2:44 PM

$MRUS $SPY $LLY $REGN

0 · Reply

Bullish_Trader555 Oct. 24 at 2:09 PM

0 · Reply

MahiMe Oct. 24 at 1:00 PM

$REGN Canaccord Genuity has maintained a "Buy" rating for Regeneron Pharmaceuticals (REGN) with a price target of $850, as of an analyst note published on October 23, 2025

0 · Reply

RyanWalker8333 Oct. 23 at 9:49 PM

Instinct: pressure building, could ignite fast! Portfolio: $GS $BNTX $REGN $SAP $RIO Why this cluster: Liquidity profile looks favorable for quick repricing once momentum confirms. GS shows relative strength; BNTX is base-building; REGN is a stealth accumulator; SAP offers sector exposure; RIO provides stability. Execution: Execution: define stop levels, use partial profit-taking on initial leg. #StocksToWatch #Momentum Source: https://stocktwits.com/JacquelineBryant4972/message/632828478

0 · Reply

KayleeAcosta1722 Oct. 23 at 8:18 PM

High-conviction cluster — risk-defined entries only! Portfolio: $PANW $BA $REGN $EXC $SLB Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. PANW shows relative strength; BA is base-building; REGN is a stealth accumulator; EXC offers sector exposure; SLB provides stability. Execution: Execution: define stop levels, use partial profit-taking on initial leg. #TradeSetup #Watchlist Source: https://stocktwits.com/GaryBrown7417/message/632828520

2 · Reply

OX50 Oct. 23 at 7:25 PM

$REGN Fidelity has REGN score on a very high bullish rating. Time to load up huge. Very Bullish 9.6 out of 10

0 · Reply

Whiskeyunderthebed Oct. 23 at 5:54 PM

$REGN has anybody contacted investor relations regarding when they will resume production of Eylea HD dual syringe at the Catalent facility? This is taking way longer than Len said during his last Quarterly call.

0 · Reply

DannySmith6941 Oct. 23 at 4:56 PM

High-conviction cluster — risk-defined entries only! Portfolio: $FTNT $OKTA $MRK $REGN $ABNB Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. FTNT shows relative strength; OKTA is base-building; MRK is a stealth accumulator; REGN offers sector exposure; ABNB provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #RiskManaged #TopPicks Source: https://stocktwits.com/JacquelineBryant4972/message/632828478

0 · Reply

Yeueehehe Oct. 23 at 4:29 PM

$REGN welcome to the hell bro

1 · Reply

KristenVillanueva2032 Oct. 23 at 4:16 PM

Tape is smoking — catalysts near, volume rising! Portfolio: $GOOGL $HAL $BKNG $LI $REGN Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. GOOGL shows relative strength; HAL is base-building; BKNG is a stealth accumulator; LI offers sector exposure; REGN provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #StocksToWatch #Momentum Source: https://stocktwits.com/TiffanyLawson6758/message/632828686

0 · Reply

BryanNewton Oct. 23 at 2:34 PM

$REGN what a garbage stock. Can't even go green when markets are ripping. Falls harder when markets are bleeding

0 · Reply

Whiskeyunderthebed Oct. 23 at 2:26 PM

$REGN still holding this thing hostage...

0 · Reply

MahiMe Oct. 23 at 1:36 PM

$REGN Canaccord Genuity maintains a Buy rating on Regeneron Pharmaceuticals (REGN) with a price target of $850 on oct 23,2025.

0 · Reply

JarvisFlow Oct. 23 at 1:04 PM

Canaccord Genuity has updated their rating for Regeneron Pharmaceuticals ( $REGN ) to Buy with a price target of 850.

0 · Reply

MahiMe Oct. 23 at 11:46 AM

$REGN https://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-regn-stock-holdings-increased-by-ethic-inc-2025-10-23/

0 · Reply

Market Cap	61.02B
Revenue (ttm)	14.20B
Net Income (ttm)	4.41B
EPS (ttm)	N/A
PE Ratio	15.08
Forward PE	18.21
Profit Margin	31.07%
Debt to Equity Ratio	0.07

Volume	875,400
Avg Vol	1,036,166
Day's Range	N/A - N/A
Shares Out	105.99M
Stochastic %K	68%
Beta	0.31
Analysts	Strong Sell
Price Target	$730.42